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Abstract
 
T cells directed against minor histocompatibility antigens (mHags) might be responsible for
eradication of hematological malignancies after allogeneic stem cell transplantation. We investigated
whether transfer of T cell receptors (TCRs) directed against mHags, exclusively expressed on
hematopoietic cells, could redirect virus-specific T cells toward antileukemic reactivity, without
the loss of their original specificity. Generation of T cells with dual specificity may lead to survival
of these TCR-transferred T cells for prolonged periods of time in vivo due to transactivation of
the endogenous TCR of the tumor-reactive T cells by the latent presence of viral antigens.
Furthermore, TCR transfer into restricted T cell populations, which are nonself reactive, will
minimize the risk of autoimmunity. We demonstrate that cytomegalovirus (CMV)-specific T
cells can be efficiently reprogrammed into leukemia-reactive T cells by transfer of TCRs directed
against the mHag HA-2. HA-2-TCR–transferred CMV-specific T cells derived from human
histocompatibility leukocyte antigen (HLA)-A2
 
  
 
or HLA-A2
 
  
 
individuals exerted potent anti-
leukemic as well as CMV reactivity, without signs of anti–HLA-A2 alloreactivity. The dual
specificity of these mHag-specific, TCR-redirected virus-specific T cells opens new possibilities
for the treatment of hematological malignancies of HLA-A2
 
  
 
HA-2–expressing patients trans-
planted with HLA-A2–matched or –mismatched donors.
Key words: T cell receptor • gene transfer • minor histocompatibility antigen • 
virus-speciﬁc T cells • leukemia reactive
 
Introduction
 
Donor lymphocyte infusion (DLI) into patients with a relapse
of their leukemia or myeloma after allogeneic stem cell
transplantation has been proven to be a successful treatment
strategy (1–3). The beneficial graft versus leukemia effect of
donor lymphocytes, however, is often accompanied by
GVHD. Adoptive transfer of antigen-specific T cell lines
may eradicate the relapsed hematological malignancy and
can separate the antileukemic effect from GVHD (4). The
main drawback of adoptive therapy is the difficulty to produce
sufficient quantities of antigen-specific T cells. In addition,
the specificity of the infused T cells is difficult to control.
An alternative strategy might be to equip donor T cell
populations with a TCR of defined antitumor specificity.
Dembic et al. (5) were the first to show that transfer of the
TCR into recipient T cells resulted in redirected antigen
specificity of these T cells. Since then several groups have
demonstrated that transfer of virus-specific or tumor antigen–
specific TCRs resulted in T cell populations with redirected
antigen specificity (6–12). Transfer of TCRs specific for
class I–restricted antigens into CD8
 
  
 
T cells and transfer of
TCRs of class II–restricted specificity into CD4
 
  
 
T cells
leads to functional redirected T cells, exerting antigen-specific
cytolytic activity as well as antigen-specific cytokine secretion.
Stanislawski et al. (11) demonstrated that TCR gene transfer
can be used to circumvent self-tolerance of autologous T
cells to tumor-associated antigens by transferring a humanized
MDM2-specific TCR selected from HLA-A201 transgenic
mice. Furthermore, TCR transfer studies have demonstrated
that retroviral transfer of high avidity TCRs into T lym-
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NGF-R, truncated form of the nerve
growth factor receptor; CML, chronic myeloid leukemia; DLI, donor
lymphocyte infusion; EBV-LCL, EBV-transformed B cell; eGFP, enhanced
green fluorescent protein; HPC, hematopoietic progenitor cell; MFI,
mean fluorescence intensity; mHag, minor histocompatibility antigen;
MSC, mesenchymal stem cell; PHA, phytohemagglutinin; PIA, progenitor
cell inhibition assay. 
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phocytes is accompanied by the maintenance of the paren-
tal T cell avidity and that TCR-transferred T cells exhibit
no change in the peptide-fine specificity in comparison to
the parental T cell clones (12, 13). Recently, the feasibility
of cellular therapy using TCR-modified T cells was dem-
onstrated in a mouse model system (14). In this study it was
demonstrated that T cells that were redirected by TCR
gene transfer can be activated in vivo, home to effector
sites, and contribute to tumor clearance.
Although the approach of TCR transfer appears to be
feasible, various potential problems may occur. First, the
pairing of the retroviral-introduced TCR chains with the
endogenously expressed TCR chains can lead to the for-
mation of new TCR complexes with undesired specifici-
ties. Modification of highly polyclonal T cell populations
will result in a diverse set of new specificities. This may
lead to the production of T cells that have self-reactive
TCRs that may lead to autoimmunity. Second, TCR
transfer of ignorant self-specific T cells may lead to autoag-
gressive T cells after triggering through the exogenous
TCR. In addition, if antigen-specific TCRs are transferred
into unselected primary T cells not only might a potentiat-
ing immune response develop, but also suppressive T cell
reactivity may develop, due to TCR transfer into naive T
cells or suppressor T cells. Furthermore, end-stage effector
cells with limited proliferative capacity that will be trans-
duced with the exogenous TCR may only exhibit short-
term cytolytic activity.
Based on these various reasons, we propose to redirect
the specificity of virus-specific T cells toward antileukemic
reactivity using TCR gene transfer. T cells directed against
viruses with a latent persistence in vivo like CMV and EBV
would be attractive candidates to use. These virus-specific
T cells will have an additive advantage because they will
also be triggered by the endogenous virus-specific TCR
and therefore we hypothesize that these T cells will survive
for prolonged periods of time in vivo
 
.
 
In this study we redirected virus-specific T cells into leu-
kemia-reactive T cells by the transfer of TCRs derived
from T cell clones specific for the minor histocompatibility
antigen (mHag) HA-2. mHags are derived from genetically
polymorphic proteins that can be differentially expressed
between donor and recipient (15). Because the HA-2
mHag is exclusively expressed on cells of the hematopoietic
lineages (16), T cells directed against HA-2 can be used to
treat hematological malignancies relapsing after allogeneic
stem cell transplantation when the patient is HA-2
 
  
 
and the
donor is HA-2
 
  
 
(17). T cells directed against HA-2 will
eliminate the hematopoietic cells from the patient, includ-
ing the malignant cells, without affecting donor-derived
hematopoiesis or directly affecting nonhematopoietic tissue
of the patient.
Because a high percentage of the human population ex-
press the HA-2 (18), this mHag is not frequently useful for
induction of HA-2–specific T cells in transplantations be-
tween HLA-identical individuals. However, in HLA-A2
mismatch transplants in which patient hematopoietic cells
are HLA-A2
 
  
 
and express the mHag HA-2, whereas the
donor cells do not express the HLA-A2 restriction mole-
cule, donor T cell responses might be generated against
mHag HA-2 peptide presented in HLA-A2. Several studies
have shown the in vitro generation of antigen-specific T
cells that are restricted by nonself HLA molecules (19–23).
However, stimulation with nonself HLA molecules also in-
duced undesired allo-HLA–specific T cells, which can
cause damage of all HLA-A2
 
  
 
hematopoietic and nonhe-
matopoietic tissues (20, 24). Transfer of mHag-specific
TCRs into virus-specific T cells from the donor would be
a strategy to circumvent the undesired induction of allo-
HLA–specific T cells. Because the mHag-specific TCRs
were isolated from T cells exhibiting an immune response
in an HLA-identical setting, the risk of transfer of TCRs
that not only have mHag specificity but also anti–HLA-A2
reactivity will be minimized.
In this study we explored the possibility to transfer HA-
2–specific TCRs into various HLA-restricted virus-specific
T cells derived from HLA-A2
 
  
 
and HLA-A2
 
  
 
individuals.
We demonstrated that HA-2-TCR–transduced virus-spe-
cific populations exerted significant virus-specific as well as
antileukemic reactivity without the appearance of anti–
HLA-A2 reactivity.
 
Materials and Methods
 
T Cell Clones and Cell Lines.
 
The HLA-A2–restricted T cell
clones HA2.5 and HA2.27 specific for the mHag HA-2 were iso-
lated from the peripheral blood of a patient with chronic myeloid
leukemia (CML) during an ongoing graft versus leukemia re-
sponse after DLI (17). The allo-HLA-A2–specific T cell clone
MBM13 was derived from a mixed lymphocyte reaction with pe-
ripheral blood from haploidentical siblings by limiting dilution
analysis (9). The HLA-A2
 
  
 
HFF fibroblast cell line was derived
from the American Type Culture Collection (ATCC). COS and
293 EBNA cell lines (ATCC) were transduced with a retroviral
vector encoding for the HLA-A2 molecule (9). Mesenchymal
stem cells (MSCs) were derived from the bone marrow of CML
patients by culturing the adherent cells for several weeks on
DMEM supplemented with 
 
l
 
-alanyl-
 
l
 
-glutamine, sodium pyru-
vate, 1 mg/ml glucose, pyridoxine (GIBCO BRL), and 10% FBS.
 
Generation of Retroviral Vectors and Virus Supernatant.
 
By RT-
PCR, using primers that cover the complete repertoire of known
TCR chains (25), the TCR 
 
  
 
and 
 
  
 
usage of the mHag HA-2–
specific HA2.5 was determined. The T cell clone expressed two
in-frame gene transcripts, TCR AV15S1 and TCR BV18S1. The
different TCR 
 
  
 
and 
 
  
 
chains of the T cell clone were individu-
ally cloned into retroviral vectors. The Moloney murine leuke-
mia virus–based retroviral vector LZRS and packaging cells
 
 
 
-NX-A were used (26). Two bicistronic retroviral vectors were
constructed in which the multiple cloning site is linked to the
downstream internal ribosome entry sequence and the marker
gene enhanced green fluorescent protein (eGFP; reference 27) or
truncated form of the nerve growth factor receptor (
 
 
 
NGF-R;
reference 28). The TCR 
 
  
 
chain was cloned into the retroviral
vectors in combination with eGFP and the TCR 
 
  
 
chain was
cloned in combination with the 
 
 
 
NGF-R. Retroviral vectors
encoding eGFP or 
 
 
 
NGF-R alone were used as control vectors
in the experiments. In addition, the gene product of the lower 
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matrix protein pp65 of HCMV AD169 (provided by E. Wiertz,
Leiden University Medical Center, Leiden, Netherlands) was
cloned into the retroviral vector in combination with eGFP. The
constructs were transfected into 
 
 
 
-NX-A cells using calcium
phosphate (Life Technologies) and 2 d later 2 
 
 
 
g/ml puromycin
(CLONTECH Laboratories, Inc.) was added. 10–14 d after
transfection, 6 
 
  
 
10
 
6 
 
cells were plated per 10-cm Petri dish in 10
ml IMDM supplemented with 10% FBS without puromycin.
The next day the medium was refreshed and the day after retro-
viral supernatant was harvested, centrifuged, and frozen in ali-
quots at 
 
 
 
70
 
 
 
C.
 
Retroviral Transduction of Virus-specific T Lymphocytes and Selec-
tion of Transduced T Cells.
 
Virus-specific T cells were isolated
from the peripheral blood of healthy individuals. After informed
consent PBMCs were harvested and labeled with tetrameric com-
plexes for 2 h at 4
 
 
 
C in RPMI without phenol, supplemented
with 2% FBS, washed three times, and sorted at 4
 
 
 
C using the
FACS Vantage™ (Becton Dickinson). Tetramer
 
  
 
T cells were
stimulated with either 800 ng/ml phytohemagglutinin (PHA;
Murex Diagnostics) and 100 IU/ml IL-2 (Chiron Corp.), or with
virus peptide–pulsed autologous PBMCs and 100 IU/ml IL-2.
The autologous PBMCs were pulsed with 10 
 
 
 
M CMV peptide
for 1 h, irradiated (30 Gy), and washed, and 10
 
6 
 
peptide-loaded
autologous PBMCs were added to each well of a 24-well plate
containing 2 
 
  
 
10
 
5 
 
virus-specific T cells. After 2 d of culture, the
T cells were transduced with retroviral supernatant. The transduc-
tion procedure used for the peripheral blood T cells was based on
the use of recombinant human fibronectin fragments CH-296
(29) and has been described (27). In brief, 10
 
6 
 
T cells were cul-
tured on CH-296–coated 24-well nonculture-treated plates (Fal-
con) together with 1 ml thawed retroviral supernatant for 6 h or
overnight at 37
 
 
 
C, washed, and transferred to 24-well tissue cul-
ture plates. The transduction efficiency as measured by the expres-
sion of the markers eGFP and 
 
 
 
NGF-R was analyzed by flow cy-
tometry 3–5 d after transduction. In addition, flow cytometric
analyses were performed with the relevant tetrameric complexes.
HA-2-TCR–transduced virus-specific T cells were FACS
 
® 
 
sorted
on bases of marker gene expression or HA-2 tetramer
 
  
 
staining,
and cultured at 1 cell/well (clones) or 25 cells/well (cell lines) in
IMDM supplemented with 10% human serum. Sorted T cells
were nonspecifically stimulated every 2 wk with feeder cell mix-
tures containing irradiated allogeneic PBMCs (30 Gy), irradiated
EBV-transformed B cells (EBV-LCLs; 50 Gy), 800 ng/ml PHA,
and 100 IU/ml IL-2, or stimulated with virus peptide–pulsed irra-
diated autologous PBMCs (30 Gy) and 100 IU/ml IL-2.
 
Tetrameric HLA Class I/Peptide Complexes, Flow Cytometric
Analyses, and FACSort™.
 
PE- or APC-conjugated tetrameric
complexes were constructed as previously described (30) with
minor modifications. Tetrameric HLA-A2 molecules in complex
with CMV pp65–derived peptide NLVPMVATV (CMV
 
A2 
 
tet-
ramer) and HA-2–derived peptide YIGEVLVSV (HA-2
 
A2 
 
tet-
ramer) were constructed. In addition, tetrameric HLA-B7
molecules in complex with CMV pp65–derived peptide
TPRVTGGGAM (CMV
 
B7 
 
tetramer) were constructed. For flow
cytometric analyses as well as FACSort™ experiments, cells were
labeled with tetrameric complexes for 2 h at 4
 
 
 
C in RPMI with-
out phenol, supplemented with 2% FBS, and washed three times.
During the last 30 min, mAbs directed against the various cell
surface molecules were added. The mAbs used were anti-CD4
(FITC), anti-CD8 (FITC or PECy5), anti-CD40 (FITC), and
anti–NGF-R (PE; all from Becton Dickinson).
 
Cytotoxicity Assay.
 
Target cells were harvested, labeled with
50 
 
 
 
Ci Na
 
2
51 
 
CrO
 
4 
 
for 60 min at 37
 
 
 
C, washed three times, and
added to various numbers of effector T cells in a final volume of
150 
 
 
 
l IMDM supplemented with 10% FBS in 96-well U-bot-
tomed microtiter plates. HA-2
 
  
 
and HA-2
 
  
 
EBV-LCLs, HFF,
COS, 293 EBNA cells, and leukemic cells harvested from pa-
tients after informed consent were used as target cells. In addi-
tion, EBV-LCLs transduced with a retroviral vector encoding for
the gene product of the lower matrix protein pp65 of HCMV
AD169 were used (EBV-Z pp65). In some experiments, 
 
51
 
Cr-
labeled target cells were loaded by preincubation for 1 h at 37
 
 
 
C
with different concentrations of synthetic peptides, washed, and
added to the effector cells. After 4 or 18 h of incubation of target
and effector cells at 37
 
 
 
C and 5% CO
 
2
 
, 25 
 
 
 
l supernatant was
harvested and measured in a luminescence counter (Topcount-
NXT; Packard Instrument Co.). The mean percentage of specific
lysis of triplicate wells was calculated as follows: specific lysis 
 
 
 
[(experimental release 
 
  
 
spontaneous release)/(maximal release 
 
 
 
spontaneous release)] 
 
  
 
100.
 
Liquid Hematopoietic Progenitor Cell Inhibition Assay (PIA).
 
The PIA was performed as previously described (31, 32). T cells
at a concentration of 10
 
4 
 
cells/well were cocultured with 10
 
4
 
cells/well of cell suspensions containing malignant hematopoietic
progenitor cells (HPCs) in 96-well U-bottomed microtiter plates
in a volume of 200 
 
 
 
l IMDM supplemented with 10% FBS and
multiple hematopoietic growth factors. T cells were irradiated
with 15 Gy before use, preventing their proliferation in the PIA.
HPCs collected from different CML patients were used as target
cells. After 5 d of culture, the wells were pulsed with 1 
 
 
 
Ci
[
 
3
 
H]thymidine for 18 h. Cells were harvested and the incorpo-
rated [
 
3
 
H]thymidine was measured by luminescence counter to
determine the capacity of the T cell clones to inhibit the growth
of the HPCs. The mean percentage of growth inhibition of trip-
licate wells was calculated as follows: [(1 
 
  
 
experimental cpm/
mean cpm HPC only) 
 
  
 
100%].
 
Results
 
HA-2-TCR Transfer into CMV pp65–specific T Cells Di-
rectly Isolated from Peripheral Blood.
 
To determine whether
virus-specific T cells could be isolated, retrovirally trans-
duced and expanded HLA-A2–restricted CMV pp65–spe-
cific T cells (CMV
 
A2
 
-specific T cells) were isolated from
the peripheral blood of HLA-A2
 
  
 
HA-2
 
  
 
individuals by
FACSort™ using CMV
 
A2 
 
tetrameric complexes, and T
cells were subsequently stimulated with PHA, IL-2, and al-
logeneic feeder cells. 2 d after stimulation, the T cells were
transduced with the HA-2-TCR complex derived from
the HA-2–specific HA2.5 T cell clone, and sorted at day 5
on the basis of HA-2
 
A2 
 
tetramer positivity. In addition, T
cells were transduced with the control retroviral vectors
and sorted on the basis of marker gene expression. T cells
were sorted in bulk or single cell and expanded by nonspe-
cific stimulation. Fig. 1 shows the HA-2
 
A2 
 
and CMV
 
A2 
 
tet-
ramer staining of the HA-2-TCR–transduced and control-
transduced CMV
 
A2
 
-specific T cell lines 1 wk after sorting.
The results demonstrated that the CMV
 
A2
 
-specific T cells
transduced with the HA-2-TCR and sorted on the basis of
HA-2
 
A2 
 
tetramer staining expressed both TCR complexes
at the cell surface. The mean fluorescence intensity (MFI)
of the CMV
 
A2 
 
tetramer staining was lower on the HA-2-
TCR–transduced T cells compared with the control-trans- 
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duced T cells. The MFI decreased from 265 on control-
transduced to 86 on HA-2-TCR–transduced CMV-spe-
cific T cells, indicating competition between the two TCR
complexes for cell surface expression.
 
The HA-2-TCR–redirected CMV
 
A2
 
-specific T Cells Exert
HA-2
 
A2 
 
as well as CMV
 
A2 
 
Reactivity.
 
To determine
whether the HA-2-TCR–transduced CMV
 
A2
 
-specific T
cells were able to recognize the HA-2 mHag as well as
CMV pp65 antigen, we analyzed the cytotoxicity against a
panel of different target cells. As demonstrated in Fig. 2 A,
the HA-2-TCR–modified CMV
 
A2
 
-specific T cells exerted
cytolytic activity against HA-2–expressing EBV-LCLs as
well as CMV
 
A2 
 
peptide–loaded EBV-LCLs. In contrast,
control-transduced CMV
 
A2
 
-specific T cells exerted only
cytolytic activity against CMV
 
A2 
 
peptide–loaded target
cells. By peptide titration on T2 cells we illustrated that the
CMV
 
A2 
 
peptide reactivity of the HA-2-TCR–modified T
cell populations did not significantly differ from the
CMV
 
A2 
 
peptide reactivity of the control-transduced T cells
(Fig. 2 B). The HA-2-TCR–transferred T cells displayed
similar cytolytic efficiencies toward HA-2 peptide–loaded
target cells as the original HA-2–specific T cell clone
HA2.27. These results demonstrated the dual specificity of
the HA-2-TCR–modified CMV
 
A2
 
-specific T cells.
In addition to the HA-2-TCR–modified T cell lines, we
generated HA-2-TCR–modified CMV-specific T cell
clones to analyze the expression of the two TCR com-
plexes in more detail, and to correlate this with the func-
tional activity of the individual TCR-transferred T cell
clones. As demonstrated in Fig. 3, the HA-2-TCR–modi-
fied CMV-specific T cell clones exhibited differences in
HA-2
 
A2 
 
and CMV
 
A2 
 
tetramer staining. Some HA-2-
TCR–modified T cell clones preferentially expressed the
HA-2–specific TCR (type A), whereas other T cell clones
preferentially expressed the CMV-specific TCR (type C).
Interestingly, the majority of the T cell clones showed in-
termediate expression of both TCR complexes (type B).
Although the HA-2
 
A2 
 
and CMV
 
A2 
 
tetramer staining in the
TCR-transferred T cell clones varied, the overall TCR 
 
 
 
and 
 
  
 
expression was similar, indicating that the composi-
tion of cell surface TCRs containing the endogenous and
introduced TCR chains was variable in the different T cell
clones, and not the absolute numbers of TCRs expressed.
These results indicated that the different TCR complexes
competed for cell surface expression. Importantly, the ex-
pression of the HA-2-TCR and CMV-TCR complexes
on the different T cell clones as measured by HA-2
 
A2 
 
and
CMV
 
A2 
 
tetramer staining, respectively, was stable during a
culture period of 2 mo. Furthermore, as illustrated in Table
I, which shows representative examples of each clone type,
the lytic activity of the dual-specific T cell clones correlated
Figure 1. Tetramer staining of CMVA2-specific T cells transduced with
the HA2.5-TCR or control vectors. The sorted HA-2-TCR– and control
GFP-NGF-R–transduced T cells were labeled with PE-conjugated HA-2A2
tetramers and APC-conjugated CMVA2 tetramers for 2 h at 4 C.
Figure 2. HA-2-TCR–modified CMVA2-specific T cells exert dual specificity. (A) HA-2-TCR–modified CMVA2-specific T cells, control-transduced
CMVA2-specific T cells, and the original HA-2–specific T cell clone HA2.27 were tested against EBV-LCLs expressing the HA-2 mHag (EBV-RZ),
EBV-LCLs negative for HA-2 (EBV-Z), and EBV-Z loaded with 10  M of the CMVA2 peptide at an E/T ratio of 10:1, illustrating dual recognition by
the HA-2-TCR–modified CMVA2–specific T cells. (B) The different effectors were tested against T2 cells loaded with different concentrations of HA-2A2
peptide or CMVA2 peptide. T2 cells were preincubated with peptides for 1 h at 37 C, washed, and added to the T cells at an E/T ratio of 10:1. The
results demonstrated that the virus-specific reactivity did not significantly differ between the two transduced T cell populations.Heemskerk et al. 889
in general with the TCR expression. Type A and type B T
cell clones exerted efficient HA-2–specific cytolytic activity
directed against HA-2 peptide–loaded as well as endoge-
nous HA-2–expressing target cells. Importantly, these type
A and type B T cells were CMV specific because CMV
pp65 peptide–loaded target cells as well as target cells en-
dogenously expressing the CMV pp65 protein were recog-
nized by these TCR-transduced T cell clones (Table I),
demonstrating the dual specificity of these T cell clones. In
agreement with the bright CMVA2 tetramer staining, type
C T cells exerted efficient cytolytic activity directed against
the CMV pp65  target cells. Although only minimal HA-
2-TCRs could be visualized by HA-2A2 tetramers on these
type C T cell clones, T2 cells loaded with HA-2 peptides
could be lysed by these T cells (Table I).
To predict whether stimulation in vivo with CMV-
infected cells would lead to the stimulation and expansion
of all three types of TCR-transferred virus-specific T cells,
HA-2-TCR–transferred CMV-specific T cells were stimu-
lated twice in vitro with CMV pp65–expressing stimulator
cells over a period of 30 d. As demonstrated by tetramer
staining shown in Fig. 4, the total population of HA-2-
TCR–transduced CMV-specific T cells expressed after 30 d
marked levels of CMV-TCRs as well as HA-2-TCRs at
the cell surface. Stimulation of the HA-2-TCR–transferred
CMV-specific T cells with stimulator cells endogenously
expressing the HA-2 mHag also resulted in expansion of
the TCR-transduced CMV-specific T cells. Tetramer
staining demonstrated the marked expression of both
TCRs at the cell surface, with a tendency of lower levels of
CMV-TCR expression. In parallel we stimulated control-
transduced CMV-specific T cells with stimulator cells ei-
ther expressing the CMV or the HA-2 antigen. Stimulator
Figure 3. Tetramer staining of the HA-2-TCR–modified CMVA2-
specific T clones. Representative HA-2-TCR–transferred T cell clones
were labeled with either PE-conjugated HA-2A2 tetramers (bold line) or
CMVA2  tetramers (thin line). As controls, the control-transduced
CMVA2-specific T cell clone 45E and the original HA-2–specific T cell
clone HA2.27 are shown. Three different types of HA-2-TCR–modified
CMVA2-specific T clones were identified.
Table I. HA-2A2 and CMVA2 Tetramer Staining and Cytolytic Activity of the HA-2-TCR–transduced CMV-specific T Cell Clones
T cell clones Type HA-2A2 tet CMVA2 tet
EBV-Z
HA-2-
EBV-Z
HA-2-
pp65 a
EBV-RZ
HA-2 
T2
HA-2-
T2
  CMVpep
(6E-10 M)
T2
  HA-2pep
(6E-10 M)
(MFI) (MFI) (% lysis) (% lysis) (% lysis) (% lysis) (% lysis) (% lysis)
70D A 146   78 17   12 0 15 37 0 47 27
58D B 39   17 29   17 0 24 28 0 57 30
31D C 9   2 82   47 0 45 5 0 67 16
45E — 6   3 126   9 0 46 0 0 44 0
HA2.27 — 226   73 7   20 0 3 1 0 0 3 5
HA-2A2 and CMVA2 tetramer staining (indicated as MFI) and cytolytic activity at an E/T ratio of 3:1 of representative HA-2-TCR–transduced (D
clones) and control-transduced (E clone) CMV-specific T cell clones and the original HA-2–specific T cell clone HA2.27. The tetramer stainings
were performed at different time points of culture, at least 7 d after restimulation during a period of 2 mo (n   4).
aEBV-Z retrovirally transduced with the CMV pp65 protein.
Figure 4. No loss of HA-2-TCR expression on HA-2-TCR–transduced
CMVA2-specific T cells after CMV pp65–specific stimulation. HA-2-TCR–
transduced CMVA2-specific T cells were sorted on basis of HA-2A2 tetramer
positivity and expanded for 3 wk. The HA-2-TCR–transduced T cells
were then split and stimulated twice with either CMV pp65–expressing
EBV-LCLs cells or HA-2–expressing EBV-LCLs over a period of 30 d.
T cells were labeled with PE-conjugated HA-2A2 tetramers and APC-
conjugated CMVA2 tetramers for 2 h at 4 C.From Virus-specific Toward Leukemia-specific T Cells by TCR Transfer 890
cells endogenously expressing the HA-2 mHag were un-
able to stimulate and expand the control-transduced CMV-
specific T cells, whereas stimulator cells expressing CMV
pp65 induced expansion of the control-transduced CMV-
specific T cells. In a cytotoxicity assay we demonstrated
that the HA-2-TCR–transferred T cells stimulated with
CMV pp65–expressing stimulator cells exerted, comparable
to the HA-2-TCR–transferred T cells stimulated with
HA-2–expressing stimulator cells, specific cytolytic activity
directed against HA-2–expressing target cells as well as
CMV pp65–expressing target cells (Table II), illustrating
that the dual specificity of the TCR-transferred virus-spe-
cific T cells is preserved after stimulation of either the en-
dogenous or the introduced TCR.
HA-2-TCR–transduced CMVA2-specific T Cells Exert Anti-
leukemic Reactivity. To determine whether the mHag
HA-2 specificity of the HA-2-TCR–modified CMV-spe-
cific T cells could be translated into antileukemic reactivity,
the TCR-transferred T cells were tested against a panel of
CML cells in a cytotoxicity assay. The HA-2-TCR–modi-
fied CMV-specific T cell clones were able to exert cy-
tolytic activity against HA-2–expressing CML cells and not
against HA-2  CML cells (Fig. 5 A). The cytolytic activity
of the TCR-transferred T cells was for most TCR-trans-
ferred T cell clones as efficient as the original HA-2–spe-
cific T cell clone HA2.27. The HA-2–specific TCR den-
sity, measured by HA-2A2 tetramer staining, correlated with
the ability of the TCR-modified T cell clones to lyse the
Table II. Cytolytic Activity of the HA-2-TCR–transduced 
CMV-specific T Cells after Expansion by Stimulation with 
Either CMV pp65 or HA-2
T cells Stimulationa
EBV-Z
HA-2-
EBV-Z
HA-2-
pp65 b
EBV-RZ
HA-2 
(% lysis) (% lysis) (% lysis)
Control transduced pp65 5 46 0
Control transduced HA-2 n.e.c n.e. n.e.
HA-2-TCR transduced pp65 3 27 19
HA-2-TCR transduced HA-2 0 17 22
aCMVA2-specific T cells transduced with control vectors or the HA-2-
TCR were sorted on the basis of HA-2A2 tetramer positivity or marker
gene expression and expanded for 3 wk. The HA-2-TCR–transduced
T cells were then split and stimulated twice over a period of 30 d with
stimulator cells expressing the antigen indicated. The cells were tested
at an E/T ratio of 3:1 in a 4-h cytotoxicity assay.
bEBV-Z retrovirally transduced with the CMV pp65 protein.
cNo expansion of cells to test the reactivity.
Figure 5. Antileukemic reactivity of HA-2-TCR–
transferred CMVA2-specific T cell clones. (A) HA-2-
TCR–transduced (D clones), control-transduced (E
clones) CMVA2-specific T cell clones, the original
HA-2–specific T cell clone HA2.27, and the allo-
HLA-A2–specific T cell clone MBM13 were tested
in an 18-h cytotoxicity assay against a panel of
different CML cells at an E/T ratio of 3:1. The
MFI of the HA-2A2 tetramer staining of the different
T cell clones is indicated in the table on the right.
(B) Two HA-2-TCR–modified CMVA2-specific T
cell clones, 27D and 70D, and the control clones
HA2.27 and MBM13 were tested in a liquid hemato-
poietic PIA against different CML cells at an E/T
ratio of 1:1.Heemskerk et al. 891
HLA-A2  HA-2  leukemic cells. In addition, we tested
two HA-2-TCR–modified CMV-specific T cell clones in
the liquid hematopoietic PIA, and demonstrated that these
T cell clones were able to specifically inhibit the growth of
HLA-A2   CML progenitor cells expressing the HA-2
mHag, and not the growth of HLA-A2  HA-2  or HLA-
A2  CML progenitor cells (Fig. 5 B). The specific growth
inhibition of the HA-2-TCR–transferred CMV-specific T
cells was as efficient as the original T cell clone HA2.27.
HA-2-TCR–transduced CMVB7-specific T Cells Derived
from HLA-A2  Individuals Are Cytotoxic to Leukemic Cells,
without Signs of Anti–HLA-A2 Reactivity. To explore the
possibility of an alternative strategy to treat hematological
malignancies of HLA-A2  HA-2–expressing patients trans-
planted with HLA-A2  donors, we isolated CMV-specific
T cells from an HLA-A2  individual and transferred these T
cells with HA-2-TCRs. For this purpose CMV-specific
HLA-B7–restricted T cells (CMVB7-specific T cells) were
FACS®  sorted using CMVB7  tetramers stimulated with
CMVB7 peptide–loaded, irradiated autologous PBMCs and
transduced with the HA-2-TCR derived from the HA-2–
specific T cell clone HA2.5, or with control retroviral vec-
tors. By FACS® analyses we demonstrated that a high per-
centage of CMVB7-specific T cells was transduced (49–58%)
and that the majority of HA-2-TCR   and   chain trans-
duced T cells stained with the HA-2A2 tetramer (Fig. 6).
Similar to the HA-2-TCR–transduced CMVA2-specific T
cells, the CMVB7 tetramer staining was decreased on the
HA-2-TCR–transduced CMVB7-specific T cells compared
with the control-transduced CMVB7-specific T cells. The
double marker gene  CMVB7-specific T cells transduced
with either the HA-2-TCR or with the control vectors
were sorted and cultured for an addition 10 d in IMDM
supplemented with 10% human serum and 100 IU/ml IL-2.
The expanded HA-2-TCR–transferred CMVB7-specific T
cells were tested in a cytotoxicity assay against a panel of
target cells. As can be seen in Fig. 7 A, HA-2-TCR–trans-
duced T cells were able to efficiently lyse the HA-2–
expressing EBV-LCLs (EBV-RZ) and not the HA-2–
negative EBV-LCLs (EBV-Z). To investigate whether the
HA-2-TCR–transduced CMVB7-specific T cells exerted dual
Figure 6. Efficient HA-2-TCR transfer of CMVB7-specific T cells.
The CMVB7 tetramer  sorted T cells transduced with either control retro-
viral vectors or with the retroviral vectors encoding for the HA-2-TCR
were labeled with PE-conjugated anti–NGF-R in combination with either
APC-conjugated CMVB7 or HA-2A2 tetrameric complexes. The CMVB7
and HA-2A2 tetramer stainings of the gated double marker gene  cells of
the control-transduced (thin line) and the HA-2-TCR–transduced (bold
line) CMVB7-specific T cells are shown as histogram plots. The MFI of
the CMVB7 and HA-2A2 tetramer stainings on the two gated T cell popu-
lations are indicated in the histogram plots.
Figure 7. Antileukemic reactivity
of HA-2-TCR–transferred CMVB7-
specific T cells without anti–HLA-A2
reactivity. HA-2-TCR–transduced
CMVB7-specific T cells, control-
transduced CMVB7-specific T cells,
the original HA-2–specific T cell
clone HA2.27, and the allo-HLA-
A2–specific T cell clone MBM13
were tested against a panel of different
target cells at an E/T ratio of 5:1.
(A) T cells were tested against HLA-
A2  HA-2  EBV-LCLs (EBV-Z) and
HLA-A2  HA-2  EBV-LCLs (EBV-
RZ), EBV-Z transduced with HLA-
B7 and loaded with either 10  M
CMVB7  peptide (EBV-Z B7 
CMVB7  pep) or HA-2A2  peptide
(EBV-Z B7  HA-2A2 pep) for 1 h
at 37 C, or not loaded (EBV-Z
B7 ) and HLA-B7  EBV-Z trans-
duced with the pp65 gene (EBV-Z
B7  CMV ) in a 4-h cytotoxicity assay. (B) T cells were tested against HLA-A2  CML cells (CML-BE), HLA-A2  HA-2  CML cells (CML-T), and
HLA-A2  HA-2  CML cells (CML-Z) in an 18-h cytotoxicity assay. (C) T cells were tested against HLA-A2  HA-2  HFF cells, COS and 293 EBNA
cells transduced with HLA-A2, and MSCs negative for HLA-A2 (MSC-BE), HLA-A2  HA-2  MSCs (MSC-T), and HLA-A2  HA-2  MSCs
(MSC-Z) in an 18-h cytotoxicity assay.From Virus-specific Toward Leukemia-specific T Cells by TCR Transfer 892
HA-2 and CMV specificity, similar to the HA-2-TCR–
transferred CMVA2-specific T cells, HLA-B7–transduced
EBV-Z were loaded with the CMVB7 peptide or were addi-
tionally transduced with the pp65 gene of CMV. As can be
seen in Fig. 7 A, the HLA-B7  EBV-Z target cells either
loaded with CMVB7 peptide or endogenously expressing the
pp65 protein of CMV were efficiently lysed by the control-
transduced as well as the HA-2-TCR–transduced CMVB7-
specific T cells, illustrating that the HA-2-TCR–transduced
CMVB7-specific T cells exerted dual specificity. In addition,
HLA-A2  CML cells expressing the HA-2 mHag (CML-T)
were efficiently lysed by the HA-2-TCR–modified T cells
(Fig. 7 B). In contrast, HLA-A2  CML cells negative for
HA-2 or HLA-A2  CML cells were not lysed by the HA-
2-TCR–modified T cells. No anti–HLA-A2 alloreactivity
was observed because HLA-A2  target cells negative for
HA-2, including the HLA-A2  HFF fibroblast cell line,
HLA-A2–transduced COS and EBNA cells, and the HLA-
A2  MSCs derived from the patients with CML (MSC-T
and MSC-Z), were not lysed by the HA-2-TCR–trans-
duced CMVB7-specific T cells (Fig. 7 C). In contrast, the
allo-HLA-A2–restricted control T cell clone MBM13 lysed
all of these HLA-A2–expressing target cells efficiently. In
agreement with the expression pattern of the HA-2 mHag,
the MSCs of patient T were not lysed by the HA-2–specific
T cells because MSCs in contrast to the cells derived from
the hematopoietic lineage do not express the HA-2 mHag.
These results illustrate that reprogramming of virus-specific
T cells into antileukemic reactive T cells by transfer of
mHag-specific TCRs without the occurrence of allo-HLA
reactivity is feasible.
Discussion
In this study we demonstrated the efficient reprogram-
ming of virus-specific T cells into leukemia-reactive T cells
using TCR gene transfer. HLA-A2–restricted as well as
HLA-B7–restricted CMV-specific T cells derived from
HLA-A2  and HLA-A2  individuals transferred with the
HA-2-TCR were able to exert efficient antileukemic reac-
tivity, without signs of anti–HLA-A2 alloreactivity. The vi-
rus-specific T cells were isolated by tetrameric complexes,
expanded by specific or aspecific stimulation, and transferred
with the genes encoding for the TCR directed against the
mHag HA-2 in the context of HLA-A2. The CMV-specific
T cells isolated by CMVA2 or CMVB7 tetrameric complexes
were  95% pure, could be efficiently transduced (40–60%),
and expanded vigorously. The HA-2–specific cytolytic ac-
tivity of most HA-2-TCR–transferred T cell populations
was similar to the original HA-2–specific T cell clones and
in addition, the TCR-redirected virus-specific T cells ex-
erted efficient cytolytic activity against CMV peptide–
loaded target cells or target cells that endogenously express
the CMV pp65 protein, demonstrating the dual specificity
of the HA-2-TCR–transferred CMV-specific T cells.
No anti–HLA-A2 alloreactivity was observed because
HLA-A2  nonhematopoietic cell lines, HA-2  HLA-A2 
EBV-LCLs, and HLA-A2  MSCs of patients from which
the HA-2  CML cells were derived were not recognized by
the HA-2-TCR–transferred T cells. The HA-2-TCR–
transferred T cells only exerted specific CMV as well as leu-
kemia reactivity. Therefore, we speculate that these T cells
will be useful in HLA mismatch transplantations because af-
ter these transplantations administration of unmodified HLA
class I disparate DLI has a high risk of inducing GVHD.
Regardless of whether the HA-2-TCR–transferred vi-
rus-specific T cells were stimulated with HA-2 or CMV,
no selective decrease in the HA-2-TCR expression was
observed. Based on these results and the latent persistence
of herpes viruses like CMV and EBV in vivo, we hypothe-
size that the TCR-transferred dual specific T cells exerting
both leukemia as well as virus specificity will be triggered
continuously with low doses of viral antigens via their en-
dogenous virus-specific TCR in vivo. Therefore, we spec-
ulate that due to this low dose triggering of these TCR-
transferred dual specific T cells, the T cells will survive for
prolonged periods of time in vivo. Furthermore, we hy-
pothesize that by virus-specific peptide vaccinations we
will be able to promote the survival of these leukemia-
reactive, TCR-transferred virus-specific T cells in vivo.
During CMV reactivation, there might be preferential
proliferation of TCR-transduced T cells with the highest
activity against CMV. Although the TCR-transduced
CMV-specific T cells with the highest HA-2 activity may
not expand as vigorously during CMV disease, we speculate
that these T cells will persist in the patient and during reap-
pearance of the malignancy, these T cells with the highest
HA-2–specific avidity are likely to preferentially expand.
Because in vivo the compartments in which specific viral
antigens are expressed may not be identical to the site of the
malignancy, the homing characteristics of the engineered T
cells might be a relevant factor. By selecting for TCR trans-
fer T cells specific for not only CMV but also for other tar-
get antigens like EBV, reprogrammed T cells might be di-
rected to several tissues in search of the malignancy.
An advantage of using virus-specific T cells for TCR
gene transfer is that these polyclonal T cell responses consist
of a restricted TCR repertoire. The formation of mixed
TCR dimers due to pairing of the endogenous TCR chains
with the introduced TCR chains that may have unpredict-
able specificities possibly leading to harmful immune reac-
tions, will therefore be limited. In addition, TCR transfer of
virus-specific T cells will minimize the induction of autoag-
gressive T cells that may develop due to triggering of igno-
rant self-specific T cells through their introduced TCR.
Furthermore, if antigen-specific TCRs are transferred into
unselected primary T cells not only might a potentiating im-
mune response develop, but also suppressive T cell reactiv-
ity. If naive T cell populations that are transduced with the
specific TCR encounter their stimulatory antigen in vivo in
the context of nonprofessional antigen-presenting cells, the
T cell response may abort or antigen-specific suppression
may even occur. In addition, if circulating suppressor T cells
are transduced with the specific TCR, suppression of the de-Heemskerk et al. 893
sired T cell response may develop. Furthermore, end-stage
effector cells with limited proliferative capacity that will be
transduced with the exogenous TCR may only exhibit
short-term cytolytic activity. In contrast, virus-specific mem-
ory T cells are likely to expand rapidly in vivo, and are prob-
ably destined to undergo multiple cell divisions. Therefore,
as host cells for TCR gene transfer, it may be desirable to se-
lect for memory T cell populations that apparently have been
successfully triggered in the past by professional antigen-pre-
senting cells, and are capable of further large scale expansion
in response to specific activation.
Transfer of TCR   and   chains into T cells results in
cell surface expression of the introduced TCR, the endog-
enous TCR, and mixed TCR dimers, which consist of en-
dogenous and exogenous TCR chains. If the individual
TCR   and   chains pair with similar affinity to each other
and no competition for cellular components between the
individual TCR   and    chains occurs, the introduced
TCR and endogenous TCR density on individual T cells
would be  25% of the total TCR expression for each
TCR complex. In addition,  50% of the total TCR   
expression would consist of mixed TCR dimers. The ma-
jority of the HA-2-TCR–transferred T cell clones demon-
strated intermediate expression of both the virus- and the
HA-2–specific TCR complexes, representative for the type
B T cell clones (Fig. 3). Because the TCR    cell surface
expression on these HA-2-TCR–transferred T cell clones
is similar to the TCR    expression of the type A and type
C TCR-transferred T cell clones, these results indicated
that formation of chimeric TCR complexes is occurring.
Furthermore, we demonstrated that the cell surface expres-
sion of the introduced HA-2-TCR complex in relation to
the endogenous CMV-specific TCR varied between T
cells. This might be due to differences in expression levels
of the retroviral vectors encoding for the TCR   and  
chains or due to intrinsic properties of the TCR-transferred
T cells. Preferential pairing of particular TCR   and  
chains might be responsible for the variations in TCR ex-
pression. Hence, further selection of certain virus-specific
T cells with a particular TCR   and   chain usage unable
to pair with the introduced mHag-specific TCR would
then be relevant.
In conclusion, these results demonstrated that it is possible
to redirect the specificity of virus-specific T cells toward an-
tileukemic reactivity. Based on the dual specificity of these
TCR-redirected virus-specific T cells and the minimization
of autoimmunity, TCR transfer of virus-specific T cells will
open new possibilities for the treatment of hematological
malignancies of HLA-A2  HA-2–expressing patients trans-
planted with HLA-A2–matched or –mismatched donors.
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